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In the months since our last
issue of Yale Medicine appeared,
we’ve seen a visit from our
nation’s Surgeon General (who
also happens to be a recent
alumnus); teenagers with diabetes climbing rock walls thanks
to an artificial pancreas developed by School of Medicine faculty; hackathons that seek novel
solutions to health care problems; and a new joint M.D./Ph.D.
program with the University of
Puerto Rico.
Exciting news also comes
from beyond the corner of
Cedar Street and Congress
Avenue. A member of the Class
of 2004 has been working

with indigenous people in the
Amazon rainforest to compile
an encyclopedia of medicinal plants used by shamans.
Another alumnus from the Class
of 1949, still active at the age
of 93, is seeking ways to help
doctors in training cope with
the personal and professional
stressors of a life in medicine.
A member of the Class of 1990
has taken a contrarian view
of e-cigarettes—despite their
dangers, he believes, they can
still help people quit smoking.
On a lighter note, a lunchtime
painting class offers participants a brief respite from the
office, lab, or clinic.

Chronicles of all these
activities and more are inside
the pages of our Winter issue
of Yale Medicine. As ever, we
strive to let you know not only
what’s happening on the medical school campus, but also
what our alumni, faculty, and
students are accomplishing in
New Haven and the world. And
because there’s always more
news than we can fit inside
the pages of the magazine, we
encourage you to visit us online
for more events and discoveries
from the School of Medicine.
John Curtis
Editor, Yale Medicine
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dialogue

		 The machinery of medicine:
how technology influences
medical research and clinical care
fashioned the first scalpel out of stone,
new machines and methods have changed the way we practice
medicine and learn about the human body. Physicians moved on
from those early scalpels to stethoscopes, X-rays, and MRIs, the
better to understand the workings of the human body. With these
new understandings has come translational research that transfers findings from the lab into new, more effective treatments
and medicines. Dean Robert J. Alpern, M.D., Ensign Professor of
Medicine, discussed basic science and advances in clinical care;
technology and patient care; and the role of serendipity in research
with Yale Medicine.
SINCE N EOL I T HIC H U M A NS

What have been some of the key inventions or discoveries that have advanced
clinical care and medical research? In the past 50 to 100 years, there have been
so many advances that it’s hard to rank any one above the other. Obviously,
some come to mind—the discovery of the structure of DNA, recombinant DNA,
electron microscopy, knockout technology. The new gene editing technology,
CRISPR, is really going to transform research. It’s important to point out that
the major advances in health care have been based on basic scientific findings.
DNA technology and the structure of DNA were basic science findings that now
drive clinical genetics. The understanding of how cells grow has transformed
cancer care. Basic understandings of the immune system have led to immunotherapy for cancer.
How do physicians integrate new technologies into medicine while maintaining
the doctor-patient relationship? Technology is always good for improving what
physicians can do, but you run the risk that doctors won’t hone their clinical
skills as well as they could because they know that the technology will end up
defining the diagnosis. There needs to be a combination of the two. I don’t see
technology replacing the need for outstanding clinicians. Technology should
enhance clinical skills, not replace them.
How important is serendipity in scientific discovery? There are stories of serendipity, but the best investigators always appear to have good luck. The best investigators are asking the right questions, the important questions. It’s a matter of
staying knowledgeable about all of the technologies, including those from other
fields, and thinking about how to apply them to your field. When you ask the
right question and use the right technology, serendipity falls upon you.
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»

		
Our collective will, says
the Surgeon General, can give
“every man, woman, and child
		
a fair shot at good health”
W H E N V I V E K H . M U R T H Y, M .D. ’03, M .B . A . ’03,

returned

to Yale in September, it was his first visit to his alma mater
in the navy blue uniform of the U.S. Surgeon General. As he
walked through the campus during his two days at Yale, he
encountered constant reminders of the five years he spent
in New Haven as a student—the shade tree on Hillhouse
Avenue where he studied and wrote in his journal; the lecture hall where a classmate was so intent on taking notes
that he never noticed when the professor called on him; and
the former teachers who are now his colleagues.

After his talk in Harkness
Auditorium, Surgeon
General Vivek Murthy
posed for a selfie with
Neil Pathak, a first-year
medical student, and
Rachel Solnick, a resident
in emergency medicine.
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During a talk in Harkness
Auditorium, one of four he gave
in New Haven, Murthy fielded a
question from Cary Gross, M.D.,
professor of medicine, who said,
“Welcome back. You’ve made us
all proud.”
Murthy turned to the audience and said, “Dr. Cary Gross
was, in fact, my thesis advisor.”
And to Gross, “I just had a flashback to sitting in your office.”
The exchange was a reminder
that Murthy is just 12 years out
of med school and one of the
youngest surgeons general in
recent history. And that his ties

to the School of Medicine are
both recent and strong. “It really
feels like coming home,” he
said. “I spent five years here,
exploring new ideas, meeting
new people.”
He came at the invitation of
Howard P. Forman, M.D., M.B.A.,
a mentor since Murthy’s student
days. “He agreed immediately,”
said Forman, professor of radiology and medical imaging, of

JERRY DOMIAN PHOTO

economics, of management, and
of public health, and director of
the M.D./M.B.A. Program. “It was
just a matter of finding the time.”
In Murthy’s talks at Yale and at
Gateway Community College, he
advanced his vision of a healthy
nation—one that relies on partnerships and collaborations that
may seem like strange bedfellows.
Take shopping malls. For many of
us, they symbolize consumerism
and crass consumption. Others
see them as a convenient place to
shop or hang out, a place where
you can buy everything from
handbags to sleeping bags, enjoy a
meal, and take in a movie.
Murthy sees a partner.
Such a seemingly offbeat collaboration is central to Murthy’s
vision of a healthy America, one
that he outlined in his multiple
appearances in September. He
stopped first at the School of
Epidemiology and Public Health
on September 16, followed by a
talk that afternoon at the School
of Management. The next day he
joined a panel (which included
city and state health officials)
at Gateway Community College
to discuss antismoking efforts.
That afternoon he spoke at the
School of Medicine in the same
Harkness Auditorium where, as
Forman noted, he’d donned his
first white coat.
It was at the School of
Management that Murthy discussed the partnership he’s seeking with owners and operators of
shopping malls. His vision starts
with his belief that all things in
life—from taking a walk in your

neighborhood to nurturing your
dreams and passions—stem from
good health. “Health is the common thread that weaves through
everything that we do,” he said.
“If we don’t have health, we don’t
have anything else.”
If all things flow from health,
then it behooves all of society—
not just doctors and nurses and
public health experts—to take
an active role in keeping people
healthy. All of us have a part to
play, whether we know it or not.
Murthy recognizes that health
is a complex issue that must
take into account more than
blood pressure readings and our
body mass index. Good health
also means access to healthful
food, the ability to exercise, and
freedom from poverty—in other
words, addressing the inequities
and disparities in our society.
But Murthy remains undaunted.
“We are used to thinking that
complex problems require complex solutions,” he said. “That
is not always the case.”
In all his presentations, he
broke down large problems into
manageable pieces and suggested
solutions that usually involve
some sort of collaboration. As
Surgeon General, Murthy seeks
to harness the power of eclectic
partnerships among apparently
disparate sectors of society—like
the Indiana community in which
police, educators, and public
health leaders work together
to tackle an epidemic of opiate
abuse. “We can’t prosecute our
way out of the problem,” Murthy
said of drug abuse. “It is not a

moral failing. It is something
that requires treatment.” Other
examples of the times when
“we get it right” include a program in Virginia that introduces
students to fresh vegetables,
and another that doubles the
value of food stamps at farmers’
markets, making fresh produce
more accessible.
One of Murthy’s favorite
solutions is walking, part of
“restoring a culture of physical activity.” Just 22 minutes of
walking a day, he said, greatly
reduces the risk of heart disease
or diabetes.
“Walking is one of the most
powerful things we can do as a
society to roll back the wave of
chronic disease we are facing,”
he said. That’s why he’s been
partnering with mall owners to
implement walking programs.
“When it’s incredibly hot or
incredibly cold, where better
to walk than in a mall? You can
do it with other people. It’s a
social event.”
A healthy society, he believes,
can be achieved through “collective will,” the force that led
a band of colonists to take on
the British Empire; a nation to
take on racial discrimination;
and medicine and science to
take on the HIV epidemic. With
collective will, he said, we can
improve health for all. At the
medical school, he called on the
future physicians to join him by
seeing themselves in a new role
as leaders in their communities
who bring together resources
and experts. “That shift from
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Med students add
Medical French to their
arsenal of skills.
Medicine in the wild:
students learn how to
treat ailments in the
outdoors.
Full stories and event
photo galleries, as well
as other online-only
content, can be found
on our home page at
yalemedicine.yale.edu.

being individual providers of
care to being leaders who can
communicate and convene—that
is a cultural shift, an important
one, and one that I’m hopeful
we can achieve,” he said.
“What kind of country do
we want to build with our collective will?” he continued.
“I see a country where every
man, woman, and child has a
fair shot at good health. Never,
ever believe that this challenge
is bigger than our collective will.
… Together we can translate this
vision into reality.”
—John Curtis

»

An encyclopedia
of medicine
from the Amazon

When a member of the Amazon
Matsés tribe develops the telltale sore of the parasitic disease
leishmaniasis, the tribal shaman
knows what to prescribe: heated
scrapings from the outer bark of
a particular vine. For untold generations, this indigenous group
on the Peru-Brazil border has
counted on the forest’s vast array
of medicinal plants and animals
to treat its maladies and enhance
survival practices like hunting.
But the tribe’s self-sufficient
healing tradition and the forest it depends on are under
threat. Recent sustained contact with the outside world has
rapidly led to cultural erosion,
discrimination, and resource
grabs by outsiders, hurting the
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tribe’s self-sufficiency and its
relationship to the land. Worse,
the elderly shamans who know
the rainforest’s secrets are
dying, and their knowledge is
becoming lost even as the tribe
depends on them for health
care. And because of shame
learned from missionaries who
viewed traditional healing as
“witchcraft,” until recently no
younger Matsés were training to
become shamans.
They are now. Thanks in
part to Acaté Amazon Conservation, a nonprofit co-founded
by Christopher N. Herndon,
M.D. ’04, the tribe has captured
and preserved its elders’ knowledge and inspired its youth by
writing an encyclopedia, one
intended for use in training the
next generation of tribal healers. The encyclopedia—which
Herndon believes is the fi rst
ethnobotanical inventory of
an Amazonian tribe to be written by the indigenous people
themselves—describes hundreds
of plants in 500 pages of text,

Christopher Herndon
learns about medicinal
plants on a rainforest
trail from Cesar Necqua,
a shaman from the
Matsés village of Esitrón
in the Peruvian Amazon.

Herndon played a role in
producing an encyclopedia of such plants,
and Esitrón is the village
where an apprentice
program was piloted to
pass on this knowledge.

photographs, and illustrations.
Filled with pride and optimism
in the wake of the project, several young Matsés have now
stepped up to apprentice to shamans, Herndon reported.
“With the medicinal plant
knowledge disappearing fast
among most indigenous groups
and no one to write it down, the
true losers in the end are tragically the indigenous stakeholders themselves,” Herndon
said. “The methodology developed by the Matsés and Acaté
can be a template for other
indigenous cultures to safeguard
their ancestral knowledge.”
That methodology was
entirely homegrown. To compile the encyclopedia, five
elderly shamans paired off with
younger tribe members literate
in the Matsés language. Over
two years, the elders divulged
all they knew about pharmaceutical organisms, diagnoses, and
treatments, while the youths
took notes and photographs.

ANTONIO JIMENE Z PHOTO

Last May, tribe members met to
compile the information into a
single document. Though Acaté
provided support, including a
laptop and help with formatting,
the project was entirely led and
undertaken by the Matsés.
Significantly, the tome is in
the Matsés language—whose
written version was developed
by missionaries in order to
translate the Bible—but it won’t
be translated.
That’s a measure to protect this traditional body of
knowledge from commercial
exploitation, a practice some call
biopiracy and one the Matsés are
all too familiar with. The rainforest’s pharmaceutical gifts are
legion, including the antimalarial drug quinine, the muscle
relaxant curare, and the stimulant cocaine, among others.
Westerners eager to explore
them further don’t always take
tribal interests into account. In
the early 2000s, without permission from or sharing with
the tribe, a Seattle company and
others patented versions of several peptides from the Acaté frog
(Phyllomedusa bicolor)—whose
skin secretions the Matsés use
to alter consciousness, heighten
senses, and confer feelings of
strength and courage—for use as
painkillers. Another substance
in the public domain used by the
Matsés and neighboring tribes
is bëcchëte, a type of milkwood
whose secretions applied to
the eyes are reported to help
hunters better distinguish textures. Seeds from this plant are

now sold on the Internet by nonMatsés. Herndon said he can’t
disclose Matsés remedies due to
Acaté’s agreement with the tribe.
Ethnobiology and ethnomedicine have long emphasized
the importance of cataloging
traditional plant uses, said Yale
anthropology professor Claudia
Valeggia, Ph.D., who studies the
health of Latin American indigenous groups. What makes the
encyclopedia unique, she said, is
that its monolingual nature will
keep it within the community.
“This is an invaluable survival
kit, not only literally—it can save
lives and alleviate a lot of suffering—but also metaphorically
as an important aspect of the
Matsés culture.”
Herndon, a reproductive
endocrinologist in Berkeley, Calif.,
has worked with indigenous
South American tribes since he
was in medical school, initially
through a Downs Fellowship
in the summer of his first year
at Yale. For his medical student
thesis, which was awarded the
Ferris Prize on his graduation in
2004, he studied the Tiriyó people
of Suriname, a small country on
the northeastern coast of South
America, and wrote about their
knowledge of anatomy and disease as well as plants. This knowledge remains vitally important.
Though Western medicine can
be helpful in the Amazon, remote
health stations are often understocked, personnel poorly trained,
and treatment options expensive,
impractical, or able to cause
dangerous side effects.

Herndon met the Matsés in
2011 after completing his fellowship in reproductive endocrinology at the University of California,
San Francisco. In 2012 he cofounded Acaté with William Park,
an agroforester who helps the
formerly seminomadic Matsés
develop sustainable farming
techniques to adapt to their nowmore-permanent settlements.
Their health system too
may soon become more sustainable. One of the young shamanic
apprentices is also the local
government health promoter,
a vanguard of the Matsés’
next plan: to develop an integrated Western and tribal
health system that offers the
best of both worlds.
—Jenny Blair

»

Yale and University of
Puerto Rico collaborate
on M.D./Ph.D. studies

When Daniel A. Colón-Ramos,
Ph.D., arrived from Puerto Rico
to begin his Harvard undergraduate career in 1994, things
didn’t exactly go as planned.
Moving to the campus early for
a summer program, he took a
taxi from Logan Airport into
Cambridge. But once in his
dorm room, he set down his
bags and lay on the bed feeling dizzy—and by the time
his roommate arrived, ColónRamos recalled, “I told him,
‘I’m dying. You have to take
me to the hospital.’ ”
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Harnessing the power
of online video to
promote health.
Full circle: a New Haven
high school student
returns to Yale in the
Class of 2019.
Full stories and event
photo galleries, as well
as other online-only
content, can be found
on our home page at
yalemedicine.yale.edu.

Dignitaries from Yale and
the University of Puerto
Rico, including Peter
Salovey and UPR President Uroyoán Walker,
met last summer to
discuss a new program
that would allow medical
students from Puerto
Rico to complete Ph.D.
studies in New Haven.
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No one could figure out
what was wrong. The hospital
physicians suspected meningitis, but results of a spinal tap
were negative. Eventually, said
Colón-Ramos, now an associate professor of cell biology and
neuroscience at the School of
Medicine, they tracked down his
family doctor: “It took my doctor from Puerto Rico calling the
hospital to tell them these were
all the symptoms of dengue fever.
I was coming in with a tropical
disease. They had no idea.”
Th is gap in medical knowledge was part of his inspiration
for spearheading the new M.D./
Ph.D. collaboration between
the School of Medicine and
the University of Puerto Rico
(UPR). A global context, ColónRamos believes, is necessary for
today’s health care. In this new
program, students from the
M.D. program at UPR can apply
to Yale’s Combined Program in
the Biological and Biomedical
Sciences and will be assigned

differently who will remain to
serve Puerto Rico.
Dignitaries from UPR visited Yale last July to celebrate
the new agreement. For members of the delegation, the trip
mentors while studying for
was their fi rst time to New
their doctorates in New Haven.
Haven. They met with Yale
UPR students compete for spots
President Peter Salovey after a
along with Yale’s regular appliwhirlwind day of meetings and
cant pool; the universities are
tours, fi nalizing the program,
looking for two or three stuand brainstorming more ways
dents per class to enroll in
to take advantage of the new
the program.
connections. “It’s a historical
After their fi rst year in medmoment, but it’s just the beginical school at UPR, successful
ning,” said Cruz-Correa.
applicants will spend a summer
The agreement is a fi rst point
at Yale completing an eightof contact that could open up
week lab rotation to familiarize
new opportunities for Yale’s
themselves with the campus.
medical community. It may
They’ll return to Puerto Rico
serve as a springboard for future
for two years of training, after
interactions, perhaps encourwhich the students will conduct their Ph.D. research at Yale aging students to gain medical
experience in the tropics as well
and then return to UPR for the
as connect more deeply with the
fi nal year of medical school.
New Haven community. “There
The fi rst round of applications
are many changes going on,
tagged for the program was due
defi nitely in the United States,
in December 2015. The process
but also worldwide—think
is open to students currently
about Cuba,” said Colón-Ramos.
enrolled in their fi rst year
“Patients in Puerto Rico are
of medical school at UPR, as
similar to a whole continent that
well as new students applying
lies south of the United States.
simultaneously to UPR and Yale
And really, not that different
for their M.D./Ph.D. degrees.
from communities five minutes
Training and mentoring at
down the road.”
Yale will prepare the UPR stu“We’re all very excited and
dents to create a new connected
looking forward to the rewards
community on their return.
that the students will bring
“In Puerto Rico, we don’t have
after they fi nish,” said Uroyoán
many physician-scientists,” said
Marcia Cruz-Correa, M.D., Ph.D., Walker, Ph.D., president of UPR.
director of the Office of Research He added, “We’re training our
next generation. And when I say
for the UPR School of Medicine.
ours, I mean the world’s.”
“There are other programs that
—Karen Zusi
are trying to fi ll that void, but
the gap is huge. The opportunity
to grow is dramatic.” CruzCorrea hopes that the program
will bring together medical
professionals trained to think

a collection of recent
scientific findings

C L O C K W I S E F R O M T O P L E F T: F R A N A N G , 3 S B W O R L D , M A R S B A R S , S K O D O N N E L L P H O T O S ; O P P O S I T E PA G E , M I C H A E L M A R S L A N D P H O T O

GREEN LAWNS
AND FROGS’ SEX
Neatly manicured suburban lawns and gardens are
playing havoc with the frogs’ endocrine systems,
according to a Yale study published in the Proceedings
of the National Academy of Sciences.
In 2012, researchers at the School of Forestry &
Environmental Studies counted frogs at 21 ponds in
southwestern Connecticut and found almost twice the
proportion of females being born as in forested ponds.
“The fact that we saw such clear evidence was astonishing,” said lead author and doctoral student Max
Lambert. Previous studies had found such effects from
agricultural pesticides and wastewater effluent, but
this is the first to find them in the suburbs as well.
Because some common plants naturally produce
phytoestrogens, Lambert said, just maintaining a lawn
may be a source of contamination. And other species—
wood frogs, gray tree frogs, salamanders, birds, and
turtles—may be affected as well.

FRESH VEGETABLES
AND PRIMARY CARE
It’s time to add gardening to the arsenal of clinical
skills. A nutrition workshop that was developed as part
of a new Community Engagement Curriculum had 25
internal medicine residents preparing simple, nutritious
dishes with vegetables harvested on a farm at Yale’s
West Campus. The goal is for the residents to use what
they learned to communicate more effectively with their
patients about healthful food choices.
“We want our residents to be able to offer practical
advice about local food systems and healthy eating
habits, and to enhance their abilities to integrate preventative health in their regular communications with
patients,” said chief resident Sanjeet Baidwan, M.D.,
who is leading the new curriculum with Tracy Rabin,
M.D., HS ’10; Julie R. Rosenbaum, M.D. ’96, FW ’02; and
Justin Freiberg of Yale’s West Campus.
The workshop is part of a Community Engagement
Curriculum that the Yale Primary Care Internal Medicine
Residency has undertaken, which includes communication skills, cultural awareness, home visits, and advocacy.

AFTER A HEART ATTACK,
A DISPARITY IN OUTCOMES
A study that analyzed data on more than 132,000 white
heart attack patients and almost 9,000 black patients—
and used zip codes to assess income levels—found
that the survival rate 17 years later was 7.4 percent for
white patients, but only 5.7 percent for black patients.
White patients across all ages in low-income areas
lived about 5.6 years after a heart attack, longer than
the average 5.4 years for black patients. In high-income
communities, however, the gap widened—white
patients had a life expectancy of 7 years, compared
to 6.3 years for black patients, according to the study
published in Circulation, the journal of the American
Heart Association.
The study, said lead author Emily Bucholz, M.P.H. ’09,
M.D. ’15, Ph.D. ’15, suggests that improving socioeconomic standing may improve outcomes for black and
white patients globally, but is unlikely to eliminate
racial disparities in health.

A DRUG FOR WOMEN TESTED MOSTLY IN MEN
Some scientists see a major flaw in a recent study of
the effects of alcohol consumption on a drug intended
only for women.
The study of interactions between alcohol and
Addyi, the first drug to treat female sexual dysfunction,
enrolled 23 men—and two women.
“There is no valid reason to ignore the wellestablished biological and behavioral differences
between men and women when conducting

biomedical research,” said Carolyn M. Mazure, Ph.D.,
director of Women’s Health Research at Yale. “Yet it
continues to happen.”
Sprout Pharmaceuticals, which markets Addyi, said
in a statement that the study was designed with FDA
guidance. “More men than women agreed to enroll
in this kind of study,” the statement said, adding that
Sprout plans to conduct additional studies on the
effects of alcohol in women.
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The Machinery of Medicine
OV ER T H E L A ST F E W Y E A R S, as electronic medical records have become the
norm in hospitals, clinics, and doctors’ offices, clinicians have tried to come to terms
with the computer. Is this machine demanding their attention at the expense of the
patient? How does a doctor engage her patient while typing data into a template?
The tools of medicine—from the stones that Neolithic humans honed into scalpels
to the earliest stethoscopes that emerged in the 19th century to today’s sophisticated
imaging devices—have changed the way physicians interact with their patients.
And those tools are changing biomedical research as well.
At Yale and around the world such new technologies as 3D printing or biomedical engineering have advanced medical research. But scientists still rely on hunches,
instinct, and serendipity as well as these tools. When an experiment in biomedical
engineering yielded unplanned results, the scientists didn’t scrap their findings—
they looked for a way to use what they’d found and voilà, a new approach to sunscreen. Another team tried to synthesize a compound found in a red sponge from the
Caribbean to make a medicine to block HIV infection. It took eight or nine tries, and
with each failed effort, they reevaluated and adjusted until they got it right. Physicians
at Yale spent almost 10 years developing an artificial pancreas that would control
insulin delivery for people with diabetes. Last summer they tried it out on a group of
teenagers in New Haven, with dramatic results.
In this issue of Yale Medicine we take a broad view of the machinery of medicine
to explore the ways in which physicians, scientists, and engineers work to advance
both their understanding of the human body and how they apply that knowledge
to clinical care.
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From
raw idea
to finished
product
Hackathons are great
for sparking creativity,
but turning a concept
into a marketable
product takes time.
By Christopher Hoffmann
Photographs by John Curtis and William Sacco
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JOHN CURTIS

At a hackathon in the fall of
2014, a team that included
(from left) public health
student Sharon Wu, biomedical engineering student Shari
Yosinski, School of Medicine
research associate Eydis Lima,
and biomedical engineering
students Tobi Akindoju and
Francis Mburu proposed a
dermal patch for dosing and
tracking a patient’s treatment
during a clinical trial. The
team is still pursuing the project, which is now focused on
developing a patch to detect
infectious agents. “Many of
the challenges involve time,”
says Lima, “… being a student
and trying to be an entrepreneur and finding time to think
outside the box and move the
project forward.”

From raw idea to finished product

Over the course of a frenetic weekend in March, five unlikely
colleagues—an undergrad, a nursing student, a doctoral
candidate, an employee at a marketing startup, and a hospital
resident—came together to design a device to help asthma
sufferers. Inspired by a keynote speech at a hackathon, the
initial group formed over a shared interest in asthma dosing.
Rounding out their team at lunch, they then spent the rest of
the weekend working like mad to complete their device.
The group labored until 10:30 Saturday night, returning
at about 7:30 or 8 the next morning to develop a prototype.
At one point, they sent the resident scurrying to the hospital
for an incentive spirometer, a simple instrument that measures inhalation.
The “INcentiHALER,” as they named their device, was
an easy fix to a widespread and vexing problem: the failure
of many asthma sufferers to use their inhalers properly.
Patients commonly fail to breathe in at the correct rate or
length of time, compromising the medicine’s effectiveness.
The team’s solution—simple, cheap, and elegant—was an
instrument that enables users to monitor their inhalation rate.
“We focused on how design can cue a user to have
proper technique,” said team member Angela Hasler, the
nursing student.
“Sometimes, innovation can just be a better-designed
piece of plastic housing,” added team member Justin
Koufopoulos, the marketing startup employee. “We actually
hacked together two medical devices.”
Their device garnered the grand prize at Yale’s second
biomedical hackathon in March, sponsored by the Yale Center
for Biomedical and Interventional Technology (CBIT) and
the Center for Outcomes Research and Evaluation (CORE).
The five-member team walked away with the $500 first prize,
and they appeared to be on their way.
Six months later, the “INcentiHALER” team is still working
on their project, despite some bumps in the road. The top prize
in a follow-up competition that would have provided $3,000 in
seed money—to build a prototype and apply for a patent—went
to another contestant, team member Catherine Jameson said.
Summer arrived, and the team members scattered, and other
commitments also got in the way. Jameson, for example, is
entering her senior year as an engineering major at Yale College.
But the group isn’t giving up. Since classes resumed in
September, the team has met twice, Jameson said. Their plan
is to construct a better prototype, do market research, and
then approach drug companies.
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“We’re trying to see if it’s viable and what we need to do
to make it viable,” she said. “We are fully committed to doing
everything to make it happen because we’ve gotten such positive feedback, and it would improve the patient experience.”
INcentiHALER’s experience is not uncommon for
hackathon participants, said Jean Zheng, Ph.D. ’13, CBIT’s
engineering director. Hackathons may promote innovation at
warp speed, but turning those innovations into viable products usually takes several years, she said.
And that’s just fine, said Zheng and Chris Loose, Ph.D.,
CBIT’s executive director. Hackathons are about building
excitement and energy as well as creating viable products.
“These [hackathons] are really educational at heart, and
they can lead to some great things, and have led to some
great things,” Loose said, adding that they’re just one part
of CBIT’s strategy to jumpstart biomedical innovation and
entrepreneurship at Yale.
“The purpose of the first hackathons was to create a culture of biomedical innovation,” Zheng said. “It was raising
awareness, creating excitement.”
And even though hackathons appear to focus on applying
cutting-edge technology, that’s not always the case. Grand
prizewinner INcentiHALER, for example, was about engineering, not algorithms, team member Koufopoulos pointed
out. “There are many places where just better design is
needed,” he said. “This is not always apparent at a hackathon—where that might mean ‘code’ to most people. Nearly
all of our competitors were software projects.”
Hackathons, which originated in the computer industry
and later spread to medicine, seek to speed up innovation.
Motivated, creative, and accomplished people come together
for a short period, typically a weekend. They are given a
challenge, and then they identify specific problems derived
from that challenge and pitch solutions. At the close of the
hackathon, judges give out awards in a variety of categories.
The goal of CBIT, founded in 2014, is to get the Yale
community—everyone from medical students and residents
to engineering undergraduates and Ph.D. candidates—amped
up about creating cutting-edge medical devices and computer
applications. As part of its strategy, the center teamed with
MIT Hacking Medicine, InnovateHealth Yale, CORE, and
other sponsors to hold the first-ever Yale medical hackathons,
one in October 2014 and the other in March 2015.
Organizers invited diverse groups, including residents,
doctors, nurses, doctoral candidates, and undergraduates as

J O H N C U R T I S (2)

During the 2014 Hackathon,
Yale College student Austin
Muñoz (center) and teammates (from left to right, Matt
Reagor, Amy Wong, and Dan
Freed) devised a juvenile diabetes kit with a kid-friendly
testing meter. Present to
help them were Kyle Jensen,
Ph.D., associate dean and the
Shanna and Eric Bass Director
of Entrepreneurial Programs
at the Yale School of Management, and his 5-year-old
daughter Charlotte, who
has type 1 diabetes. Wong,
CBIT executive director Chris
Loose, and Muñoz watched as
Charlotte demonstrated how
to administer insulin. Muñoz
and a friend at the School of
Architecture continued the
project, but put it on hold after they were unable to build
a medical-quality prototype.
“There’s more to hackathons
than simply building a new
app or product in a weekend,”
Muñoz says. “The relationships formed and the skills
learned are the true reward.
Failure on one idea should
never discourage someone
from continuing to solve
tough problems.”
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From raw idea to finished product

Nursing student Angela
Hasler, Yale College student
Catherine Jameson, Justin
Koufopoulos of Percolate, and
a doctoral student in biomedical engineering, Linda Fong,
won top prize for Best Patient
Experience at a hackathon in
March. The team redesigned
an asthma inhaler that would
let patients know whether
they’re using it correctly.
The team that devised the
“INcentiHALER” is still working
on the project. Their plan is
to build a better prototype,
do market research, and
approach drug companies.
“We’re trying to see if it’s viable
and what we need to do to
make it viable,” says Jameson.
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he is happy with. Some have ended up working with the Yale
Entrepreneurial Institute as well as his center to flesh out
their ideas, he said. “I think it’s going extremely well.”
Another team still working on its idea called itself
“Keep an Eye on It.” Its mobile application, developed in the
March hackathon, would allow users to take photos of skin
conditions, creating image libraries that physicians could
examine and monitor, said team member Kristen D’Angelo,
M.B.A. ’15. The app would analyze the images and provide
a social network for patients, she said. The team is focused
now on market research and recruiting iOS and Android coders to advance a prototype, she said.
D’Angelo was effusive in her praise of the hackathon,
saying she was “blown away” by the experience. “I didn’t
picture myself standing up to propose a problem, but it was
just such a welcoming environment,” she said. “The hackathon really stimulates a level of energy that lets ideas surface and grow.” /yale medicine
Christopher Hoffman is a freelance writer in North Haven, Conn.

WILLIAM SACCO

well as public health, medical, engineering, forestry, law, art,
and business students. Both events were successes, Zheng
and Loose said, producing a plethora of potential innovations.
But once the “hack” is over, the real work begins, they
said. Persistence, time, and cold hard cash are needed to
succeed. Post-hackathon, teams must build strategies to further develop their ideas, Loose said. Especially important is
determining a product’s market viability, he said.
“Defining the market means both how many patients are
in need, and how big is the final market,” Loose said. “It also
means identifying the stakeholders that need to be addressed.
The hackathon helps start that journey.”
The emphasis on entrepreneurship and market viability is
what sets hackathons apart, said Linda Fong, an INcentiHALER
team member and a doctoral student in biomedical engineering.
“Hackathons are unique in that they urge you not to focus simply
on the invention, but to also build a viable business strategy
around it,” she said. “Focusing on the inhaler actuator was our
business opportunity—most companies only care about the
drug, not the delivery.”
Of the 30 teams that took part in the two hackathons,
about five have continued their journeys, said Loose, a figure

If you have a lemon, make lemonade
When an experiment in his lab took an unexpected
turn, W. Mark Saltzman, Ph.D., saw a serendipitous
opportunity, even if the Goizueta Foundation Professor
of Biomedical Engineering and professor of cellular
and molecular physiology and of chemical engineering
wasn’t sure where it would lead. One of his postdocs
had been looking at nanoparticles that would circulate
through the blood to target tumors for drug delivery.
Instead, he found that the particles stuck to proteins
and tissues.
“That is not what we wanted them to do,” Saltzman
says. Still, his team thought they might find a use for
these sticky nanoparticles. The postdoc, Yang Deng,
Ph.D., tested them on skin samples, and found they
still stuck fast.
When Asiri Ediriwickrema, M.D. ’14, then a medical
student working in Saltzman’s lab, got a look at these
bioadhesive nanoparticles (BNPs), he saw clinical possibilities. His first thought was sunscreen.
Saltzman’s team found a way to encase an organic
sunscreen agent called padimate O inside the sticky
nanoparticles. Padimate O, the active ingredient in
many commercial sunscreens, soaks up the sun’s UV
rays, but also soaks into the skin. Nanoparticles, on
the other hand, are too large to pass through hair follicles and pores, and they remain on the skin’s surface
even when it’s wet.
Such a sunscreen could answer the concerns of
those who fear that UV-absorbing chemicals have
harmful side effects. The next step was to find an
expert on photodamage of the skin to see whether
the team’s nonabsorbent sunscreen would work. The
team knew just the person: Michael Girardi, M.D., professor of dermatology. His lab specializes in the early
events of skin cancer development, and in examining
the molecular markers of direct and indirect damage from UV exposure. “Yale is a small community,”
Saltzman says. “People know what others are doing
and you can quickly get to the person you need.”
Saltzman and his team reached out to Girardi, and
“there was instant chemistry,” Girardi says. “And a recognition that together we could accomplish so much
more than individually.”
The two labs joined forces to test the sunscreen
on mouse skin and pigskin models. “We were floored
with its performance,” Girardi says. Not only did the

sunscreen adhere to skin for up to a full day and absorb UV rays, but it did not penetrate the skin. What’s
more, the sunscreen, which used less than 5 percent
of the active agent as commercial sunscreen, proved
equally effective.
All of this means that the team is on the way to
building a longer-lasting and less toxic sunscreen.
Chemicals in commercial sunscreen can cause allergies, and have been found in urine and breast milk.
While such concerns as hormonal side effects have
yet to be proven, “a lot of people feel that if they could
avoid having these chemicals get inside the body, they
would choose to,” Girardi says. “This technology would
give them that choice.”
The team’s findings were recently published in the
journal Nature Materials, with Deng and Ediriwickrema
as co-first authors. Planning has begun for a clinical
trial, and the team has received a pilot grant to explore
the new technology further. They’ll be testing its effectiveness with other sunblock agents and addressing
additional safety concerns.
Beyond that, Girardi and Saltzman see even
greater potential for the sticky nanoparticle:
they are looking at how it might be used to
treat other skin conditions. “We have come
up with more than 100 other possible
ways to use it,” says Girardi.
—Jeanna Canapari
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Keeping the “Goldilocks” organ cool
Since the first human heart transplant nearly 50 years ago, the
standard of care for transporting donor organs has changed
little. A heart, kidney, or liver is harvested, cleaned, placed in a
cooler on ice, and shipped off via ambulance or jet plane. There
are fancier transport containers, but they can be prohibitively
expensive or too unwieldy to travel long distances. For a particular organ—the intestine—a cooler simply won’t work. These
intricate tubes demand more sophistication than a plastic bag
on ice can offer. The intestine’s complex lining, or epithelium,
“allows salts, fluids, and nutrients to go in and out on a regular
but very regulated basis,” said John P. Geibel, D.Sc., M.D., vice
chair and director of surgical research and professor of surgery (gastrointestinal) and of cellular and molecular physiology.
“You don’t want to have secretory diarrhea, and you don’t want
constipation. It’s the Goldilocks organ—[the environment] has
to be just right.”
Besides the need for a delicately balanced environment,
the intestine, teeming with bacteria, presents its own challenge. If the bacteria are not properly controlled, then parts
of the intestine can fill with toxins and kill off healthy cells,
putting the patient at further risk of infection. The problem
with the standard ice transport method, said Geibel, is
“that nobody is perfusing the tissue.” The intestine needs to
be bathed in a constantly circulating liquid.
Geibel did not have to sit on his idea for long. In 2013,
Joseph Zinter, Ph.D., associate research scientist and lecturer in the School of Engineering & Applied Science, invited
Geibel to give a presentation to his students in a medical device design class. Geibel presented his idea for an Intestinal
Preservation Unit (IPU), for which he had no prototype.
A team of students signed up to “take the back-of-thenapkin drawing to a fully functional prototype,” Geibel said.
While intestinal transplants are not as common as
those of the heart, lung, or kidney, slight improvements in
transplantation procedures could mean significant gains.
Patients who cannot absorb nutrients due to a damaged or
missing small intestine often face one option: getting nutrition through an IV or catheter.
When he met the engineering students, Geibel presented
them with an extremely lightweight cooler and challenged
them to fill in the missing pieces: a reliable battery and motor,
a system of tubes to keep liquids moving throughout the intestine, and a temperature gauge and other tools for monitoring
the status of the organ. It would be necessary to perfuse both
the main blood supply, called the mesentery, and the lumen of
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the intestine. Within weeks, the engineering team presented
a prototype, which contained a large battery and oversized top
to fit the gauges and screens. “It was still kind of kludgy, but it
was an engineering first, so we were very happy with it,” Geibel
said. After the students graduated, Geibel kept momentum going by consulting with fellow transplant surgeons on the design.
Soon, Geibel teamed up on another project with Jesse Rich and
Jen Graze, students at the School of Management. In September 2014, the team established Revai, the company behind the
medical device. By this time, Geibel and his team had tested
swine organ explants in a “version 3.0” of the transport device,
and all the animals looked healthy when examined in the histopathology lab after the transport.
To improve the design, Geibel and his team used a 3D printer
to create a cooler top that could hold the batteries, tubing, and
measuring devices, and would fit over the cooler. But the team
stopped short of reinventing the wheel for a preservation solution. They used a commercially available hypothermic solution
rather than trying to keep the liquids at body temperature.
(The field is engaged in a fiery debate about whether hyperthermic, or body-temperature, transplants should be the standard
of care rather than ice, Geibel said.) For sanitary and safety reasons, the interior of the IPU, as well as the tubing and connectors, are completely disposable. The Food and Drug Administration (FDA) requires this feature for all organ transport devices.
Transporting the intestinal organ can usually occur only
within a narrow window of two to four hours. But the Revai team
has kept an intestinal organ alive and functioning for eight hours,
Geibel said. “We want to get our box so that it can keep things
alive and keep things viable for longer periods of time,” he said.
So far, the group has reenacted an organ transplant in a
veterinary operating room. Working with medical residents
and fellows, Geibel and the Revai group watched while an
animal intestine was harvested, placed in sterile towels, and
taken to the “back table,” or what surgeons refer to as the organ transplant area. The intestine was then kept in the Revai
cooler for eight hours. The team has also tested the transport
of five donated human intestines. Without FDA approval yet,
the transplants could not be used for implantation in a reallife patient. The next step, Geibel said, will be partnering with
a high-traffic intestinal transplant center to conduct a clinical
trial. “I think the number of transplants would go up dramatically if patients knew they had a device that gave them a very
high [transplant] success rate,” Geibel said.
—Kathleen Raven

The artificial
pancreas
Ten years in its development, the artificial
pancreas is the marriage of a sensor
that monitors glucose levels and a pump
that sends insulin into the bloodstream as
needed. This device could revolutionize
how patients manage their diabetes.
By Jill Max
Photographs by Robert A. Lisak
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Rachel Hicks scrambled up the
wall at a New Haven climbing gym last spring. Hicks
has type 1 diabetes and was
participating in a test run of an
artificial pancreas that helps
her monitor her blood glucose
readings. The device, which
transmits the readings to a
smartphone device, doesn’t
interfere with normal activities.

The artificial pancreas

Last May, 15-year-old Jacob Conte was scaling a rock
wall at City Climb Gym in New Haven. Hand over
hand, grabbing onto holds protruding from the wall,
he made his way up the artificial cliff. Underneath his
clothing—indeed, under the skin on his abdomen—he
wore a small sensor that transmitted his blood glucose
level readings every five minutes to a smartphone
device in his backpack. Conte has type 1 diabetes and
requires regular infusions of insulin. The smartphone
told an insulin pump affixed to his belt when and
how much insulin to deliver. The pump—smaller than
a smartphone—injects insulin under the skin of the
abdomen through a short thin tube.
Maintaining his blood sugar control requires
constant vigilance and dozens of decisions each day.
When Conte plays football or snowboards, he has to
avoid a drop in blood sugar that could make him dizzy
or pass out. Before eating, he tests his blood sugar and
takes insulin, but if food is delayed, the insulin might
kick in too soon, causing his blood sugar to drop.
Nighttime—when more than half of hypoglycemic
(low blood sugar) emergencies occur—is especially
perilous. If he wakes up with symptoms of hypoglycemia, he tests his blood sugar and eats a snack. “It’s
kind of a burden,” he said. “Everything in my life
revolves around it.”
Handling his diabetes is about to change. The
climbing session was part of a four-day clinical trial
in which Conte and four other teenagers with type 1
diabetes took those sensors and pumps—which when
combined with a dosing algorithm are known as an
“artificial pancreas”—for a test run. Rather than a biomedically engineered organ made of tissue, the artificial pancreas is a system of devices and software that
transmits his blood glucose level readings to the device
that controls insulin delivery. Wearing the sensor and
pump doesn’t interfere with Conte’s normal activities—including climbing the rock wall, playing football,
or sleeping—and the devices are worn under his clothing, so nobody knows they’re there. Yale researchers
have been studying the artificial pancreas for the last
decade, but this spring was the first time it was tested
in pediatric patients outside the hospital—here and at
Stanford University and the Barbara Davis Center for
Childhood Diabetes in Denver.
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ABOVE The artificial pancreas
is a system of devices and
software that transmit blood
glucose level readings to a
device that controls insulin
delivery. Ten years in the
making, it was developed by
physicians and researchers at
the School of Medicine.
OPPOSITE Anthony Alvarez
also participated in the fourday clinical trial last spring.
The artificial pancreas works
with an insulin pump to adjust
delivery every five minutes in
response to glucose levels.

The artificial pancreas

closing the loop

Most of the 35 million people around the world who have
type 1 diabetes inject themselves with insulin several
times a day or use an insulin pump. The pump, which
is programmed to deliver tiny doses of insulin, has
advanced diabetes treatment. It sometimes works with
a continuous glucose monitor (CGM) that has a sensor
like the one Conte wore. Both devices are approved by
the Food and Drug Administration (FDA) but work independently of each other. The artificial pancreas closes
the loop between the two (it’s sometimes referred to as
a closed-loop system) by allowing the pump to adjust
insulin delivery every five minutes in response to the
body’s glucose levels. “The ability of the system to selfadjust automatically while patients go about their daily
lives would really be transformative in the lives of people
with diabetes,” said Stuart Weinzimer, M.D., professor of
pediatrics at the School of Medicine. Weinzimer and his
colleagues have been working on an artificial pancreas
for the last 10 years, with support from the Yale Center
for Clinical Investigation. The device tested last spring,
developed by Medtronic, is being tested at 10 centers
(of which Yale is one) in a phase III clinical trial that is
expected to lead to FDA approval in 2017.
The path to the artificial pancreas began in the late
1970s, when researchers found better ways to monitor
and control blood glucose levels. With the advent in 1977
of the hemoglobin A1C test, known simply as A1C, doctors could analyze blood sugar control over a period of
two to three months, providing a longer view than isolated blood glucose readings taken during clinic visits.
The insulin pump—first tested in a clinical trial at Yale in
1979—more closely resembled the way the pancreas produces insulin by delivering small doses throughout the
day with larger doses at meals. By the early 1980s, home
blood glucose monitoring had replaced urine testing,
and synthetic human insulin began to replace animal
insulin. But diabetes remained difficult to manage. “In
those days, when we started to be able to measure more
accurately how well controlled our patients were, most
of the numbers would have been viewed today as totally
unacceptable,” said Robert Sherwin, M.D., the C.N.H.
Long Professor of Medicine, who was on the team that
first tested the insulin pump. The pump, which gave
patients better glycemic control, gained traction in the
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early 1990s when the landmark Diabetes Control and
Complications Trial showed that controlling blood sugar
levels reduced such diabetes-related complications as
blindness, kidney failure, and neuropathy. The next
step was to replace a finger stick every few hours with
a sensor that would measure glucose continuously. “As
long as insulin delivery was not linked to changes in
blood sugar, no regimen would be perfect,” said William
Tamborlane, M.D., professor of pediatrics (endocrinology), another member of the Yale insulin pump team.
Sherwin tried to interest medical device companies in developing a sensor, but they weren’t ready to
make a financial commitment. Eventually Tamborlane,
who was also keen to develop a sensor, began working
with Medtronic to test a CGM device that received FDA
approval in 1999. In 2002, he recruited Weinzimer to
Yale to look at the possibility of combining the sensor
with a pump to develop an artificial pancreas.
a study l aunche s a projec t

While their experience with the pump gave Yale
researchers a head start, other centers were also
interested in developing an artificial pancreas. In
2006, researchers at the University of California, Los
Angeles, published the first study that combined sensor data with an algorithm to adjust insulin infusion
automatically. However, there was an inherent delay
in insulin delivery: while insulin-producing cells in
the pancreas read glucose levels every few minutes
and secrete insulin directly into the bloodstream, the
probe and the pump work via the fluid surrounding
tissue, so there is a delay in both reading blood sugar
levels and delivering insulin into the bloodstream. Still,
the study, which showed that the system could work
in adults, piqued the interest of the Juvenile Diabetes
Research Foundation (JDRF), which then launched the
Artificial Pancreas Project. The project had two arms: a
large clinical trial of CGMs co-chaired by Tamborlane,
which showed that the devices improved blood glucose
control; and another, involving Yale and four other
academic sites, to develop an artificial pancreas system.
Type 1 diabetes is typically diagnosed in children,
so the next step was to study a closed-loop system in
pediatric patients. In 2008, Weinzimer published the
results of a study involving 17 children who used an

Joanne Conte, mother of
Jacob, 15, says that with his
participation in the clinical
trial, “He’s making history.”

artificial pancreas in the hospital. A closed-loop system, the study showed, keeps blood sugar stable overnight but can’t deliver insulin fast enough at mealtime.
The solution was a manually administered extra dose at
meals, a concept that is incorporated in the Medtronic
device currently being tested.
Weinzimer presented the findings of the pediatric
study at the national JDRF conference. “People were
crying,” he said. The artificial pancreas offered hope to
parents who stay up at night worrying about hypoglycemia, which can lead to unconsciousness and even death.
Compared to today’s artificial pancreas systems—
several are in development, but Medtronic’s is furthest
along—the early systems were cumbersome. The sensors
were much larger, and a radio transmitter had to be taped
to the body and connected to a receiver plugged into a
laptop. Today, the components are compact and the systems use wireless technology to transmit sensor readings.
a need to work toge ther

Research is often a collaborative effort, and nowhere is
this teamwork more evident than in the development
of the artificial pancreas. “At first, we all did our own
thing,” said Weinzimer. “Now we’re realizing that in
order to demonstrate the safety and efficacy of these
devices on a large scale, we need to work together.”
Researchers at the University of Virginia; Boston
University; the University of California, Santa Barbara;
the University of Cambridge; Schneider Children’s
Medical Center of Israel, and elsewhere are testing
devices and designing sophisticated algorithms to finetune different systems. Yale researchers have often been
at the forefront of these efforts. Weinzimer showed that
the artificial pancreas effectively controls nighttime
hypoglycemia, while Jennifer Sherr, M.D., assistant professor of pediatrics (endocrinology), is looking for ways
to increase the system’s effectiveness at mealtimes. Says
Francine Kaufman, M.D., Medtronic’s chief medical officer and vice president for global medical, clinical, and
health affairs, “We rely on an institution like Yale with
the capability of their investigators, which is immense,
to be a push-and-pull with us.”
The artificial pancreas is based on two devices
that already existed, yet at times, progress has been
frustratingly slow. Resolving safety issues—such as

delivering too much or too little insulin—was a major
hurdle. Now increasingly tech-savvy patients are
increasing the pressure to bring a system to the market. In fact, the ability to tap into sensor data remotely
began with a group of diabetes patients and family
members who developed a software program to hack
into sensor data via a smartphone or computer.
There is also a pressing need to improve diabetes treatment despite the advances over the last 25 years. The
recommended target hemoglobin A1C level is less than
7 percent for adults, and less than 7.5 percent for those
under 19, according to the American Diabetes Association.
Yet a recent study by the T1D Exchange, a network of
more than 70 clinics dedicated to type 1 diabetes treatment and research, showed that the average adult A1C is
8.4 percent, with adolescents averaging 9 percent.
In clinical trials, the artificial pancreas helps
patients manage their blood sugar better with less
effort. “He had the best control while he was on this
closed-loop system than he’s had in the past nine
months,” said Nicole Liedke, whose 15-year-old son
was part of last spring’s clinical trial.
When the first iteration of the artificial pancreas
hits the market, the device won’t be totally automatic.
Patients will still have to instruct the pump to provide
a dose of insulin before meals to maintain optimal
blood sugar control, and the sensor has to be recalibrated twice a day. But for patients like Jacob Conte,
letting go of the reins a bit, especially at night, will
be life-changing. His mother, Joanne, who also has
diabetes, was with him during the clinical trial. “He’s
making history,” she said, as tears welled up in her
eyes. “For him and for our family, this was an unexpected opportunity of a lifetime.” /yale medicine
—Jill Max is a freelance writer in Trumbull, Conn.
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Human
body as
machine
How Yale launched
the Department of
Biomedical Engineering.
By Christopher Hoffmann
Photographs by Harold Shapiro
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When Mark Saltzman (seated,
center) began his career in
science, there was no field
called biomedical engineering. He studied chemical
engineering and learned how
to develop new ways of delivering medications. Biomedical
engineering has boomed in
recent years and Saltzman
leads a lab that includes budding researchers Heewon Suh
(seated left), (standing, left
to right) Greg Tietjen, Alice
Gaudin, Elias Quijano, Luis
Arana, Amanda King, Brittany
Thompson, Young Seo, and
Jenny Cui (seated, right).

Human body as machine

To understand biomedical engineering, says Jon S.
Morrow, Ph.D., M.D. ’76, HS ’77, FW ’80, chair and
Raymond Yesner Professor of Pathology, one must start
in the 1970s. The tools of the time confined research
to such narrow areas as a single protein or gene. “We
called it the streetlight phenomenon,” he said. “You
could only study what you could see or measure, and
it was very limited.” That began to change in the
mid-1980s and into the 1990s. Advances in computers,
computation, imaging, biology, and the completion
of the mapping of the human genome in 2003 enabled
a far deeper understanding of biological processes.
Suddenly, scientists could view and measure much
more. “You’ve got these massively parallel technologies that allowed you to see the whole landscape of
processes in large scale,” Morrow said. “Instead of a
streetlight, you had a floodlight.”
This deeper understanding elicited an “aha”
moment—the human body looked more and more like a
hugely complex machine. Researchers started applying
engineering principles to biology and clinical treatment.
“People began to realize that a biological system is just a
complicated device, and that the engineering and computer science side of things has solutions,” Morrow said.
By the late 1990s, biology and engineering had
merged into a new and exciting discipline with the
promise of everything from artificial limbs and organs
to individualized drug therapies, from medical devices
to cures for genetic diseases.
Universities around the nation were creating
departments in this innovative area, which held enormous promise for advancing medical practice and biomedical research. How would Yale respond?
Yale already had a head start. The medical school
had become a leader in imaging technology—a key
component of the new discipline. And there was interest among faculty and students in pursuing this field.
The building blocks were there; the question was how
to assemble them.
“Not only did we have experts, not only was it coming together at Yale, but it truly tapped into the needs
of the students who wanted to pursue this,” said
David A. Kessler, M.D., J.D., then dean of the School
of Medicine, and now professor of pediatrics at the
University of California, San Francisco.
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Yale was ready to jump into biomedical engineering, but key questions arose: How should Yale incorporate this new field within its existing areas of study
and research? Should it create a new department or a
stand-alone institute? If the university inaugurated a
department, should it be part of the medical school or
the Faculty of Arts and Sciences?
Kessler and the provost at the time, Alison F.
Richard, Ph.D., appointed nine senior faculty members
from the medical school and the graduate school to
form a panel to explore the possibilities.
After nine months of study, the committee issued
its report in August 1999, recommending the formation of a biomedical engineering department within
the Faculty of Arts and Sciences and tied to the medical
school. The committee rejected the stand-alone model
favored by some institutions. “They become insular,”
said Morrow, who served as one of the committee’s
two co-chairs along with Bruce McClennan, M.D., professor emeritus and biomedical imaging. “They talk
to themselves. You never learn anything by talking to
someone who does the same thing you do.”
The new department would have its own faculty;
and faculty from the medical school and elsewhere at
Yale would hold secondary appointments in biomedical
engineering. “That was a very important piece, allowing faculty the freedom to participate across schools
and disciplines, and across graduate and professional
and undergraduate boundaries,” Kessler said.
The university, including then-President Richard
C. Levin, endorsed the committee’s recommendations.
“Everyone got behind it,” Kessler said. “It was across
Yale. Nobody owned it and yet everybody owned it.”
w e d o n ’ t wa n t t o b e a n av e r a g e p r o g r a m

Yale’s new Department of Biomedical Engineering
opened its doors in 2003 within the School of
Engineering and Applied Science. The university lured
W. Mark Saltzman, Ph.D., the Goizueta Foundation
Professor of Chemical and Biomedical Engineering,
and Cellular & Molecular Physiology, from Cornell
University to serve as chair. When Saltzman graduated
from Iowa State in 1981, biomedical engineering was
not yet an established field, so he earned his undergraduate degree in chemical engineering. A pioneer

In 1999, pathologist Jon Morrow co-chaired a committee
to determine whether Yale
should create a department
dedicated to biomedical engineering. Advances in computers, computation, imaging,
biology, and the completion
of the mapping of the human genome in 2003, says
Morrow, enabled a far deeper
understanding of biological
processes and helped create
the field.

Human body as machine

Elias Quijano got hooked on
biomedical engineering while
a student at Yale College.
Now a first-year student in
the M.D./Ph.D. program, he’s
working in Saltzman’s lab
on new ways to deliver HIV
medications.
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in drug delivery and tissue engineering systems,
Saltzman relished the chance to build a department
from scratch.
“I liked the idea of starting something new at a place
where I was pretty confident it would be successful,”
said Saltzman, whose team devises novel methods for
the controlled delivery of drugs, proteins, and genes.
Saltzman’s initial goals were to hire outstanding
faculty and build a curriculum. He hired slowly, knowing that each new person would have a significant
effect on the overall department culture. Given that
the department would never be very large—today it
has about 15 members—Saltzman gave a lot of thought
to its focus. “We picked areas that we wanted to excel
in,” he said.
Saltzman settled on four: imaging, an area in which
Yale was already a leader; biomolecular engineering,
Saltzman’s specialty, applying engineering to biological
systems; biomechanics, understanding how the body
works from a mechanical engineering perspective; and
systems biology, studying biological systems as a network of components that interact with one another.
A dozen years later, the department is thriving,
Saltzman said. It has developed largely as its founders
envisioned—multidisciplinary, collegial, integrated
with the medical school, and committed to undergraduate education. The department confers about
40 undergraduate and 10 graduate degrees a year, with
an average of 50 doctoral students at some stage of
their studies at any given time. “We don’t want to be
an average program,” said Saltzman, who ended his
12-year tenure as chair on July 1. “We want to be an
outstanding program. Even though we are a young
department, I think we are judged as among the best
programs in the country. This happened fast for us
because of the strength of Yale.”
The program has produced numerous startups
and endless innovation. Saltzman cites the work
of Rong Fan, Ph.D., associate professor of biomedical engineering. Fan uses nanotechnology to “talk
to cells”’—employing tiny sensors to take dozens of
measurements of an individual cell. Saltzman also
mentions Laura E. Niklason, M.D., Ph.D., professor
of anesthesiology and biomedical engineering, who
joined the biomedical engineering faculty a decade

ago. She credits Yale with allowing her to pursue what
some might consider her “outlandish” research in lung
regeneration. “Yale’s culture is pretty good at embracing new ideas,” Niklason said.
Saltzman adds that biomedical engineering isn’t just
high-tech. A whole other aspect involves engineering a complex device, such as a ventilator for newborn
babies, into something so simple and foolproof it can
operate in a third-world hospital without reliable
access to electricity—a project now underway in the
department under the guidance of Anjelica Gonzalez,
Ph.D., the Donna Dubinsky Associate Professor of
Biomedical Engineering. Gonzalez teaches a course—
called Biotechnology for the Developing World—that
introduces students to engineering design for lowresource environments in global health.
a pa s si o n f o r b i o me d i c a l e ngi ne e r i ng

In many ways, Elias Quijano embodies the way in which
Kessler, Morrow, Saltzman, and others envisioned the
program. The son of immigrants from Ecuador and
Colombia who never attended college, Quijano arrived
at Yale College in 2008 with no interest in science.
Needing to fulfill a requirement, he took Saltzman’s
course, “Frontiers of Biomedical Engineering.” “In Dr.
Saltzman’s class, I developed a passion for biomedical
engineering and decided to study it.,” Quijano said.
“It allowed me to appreciate the contributions that an
individual can make to medicine.”
After graduating in 2012, Quijano worked on gene
therapies for cystic fibrosis in Saltzman’s lab. Now he is
a first-year student in Yale’s M.D./Ph.D. program.
“I don’t know exactly where that’s going to take me,”
Quijano said, “but I’m confident that my engineering
education will provide me with the skills to bridge the
gap between the lab and the clinic, between research
and medicine.” /yale medicine
Christopher Hoffman is a frequent contributor to Yale Medicine.
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New artery? We can print that
Mark Michalski, M.D., HS ’15, on call late one night in 2013,
was browsing through Wired when he came across an
article about 3D printing. It is, as the name suggests, a technology for printing—not ink on a sheet of paper but structures made of diverse materials in three dimensions. Then
a radiology resident at Yale-New Haven Hospital, Michalski
spent many working hours examining cross-sectional
images of the human body and body parts. These images, taken from computed tomography (CT) and magnetic
resonance imaging (MRI) scans, depict the body as if it were
cut up into many thin slices; taken together, they represent
three-dimensional structures. Most of the time, surgeons
scroll through these images to create mental pictures of the
anatomy that they will meet in 3D only in the operating room.
3D printing, Michalski realized, offered a new possibility:
custom-printed 3D models, which surgeons could handle
and experiment with, of the structures that they would later
cut, stitch, and screw together.
“I thought to myself, ‘Well, I have a lot of the raw materials here; I wonder if I can just start printing things,’ ” recalls
Michalski. “Of course, it wasn’t that simple.”
Since then, Michalski and other radiologists at Yale have
used 3D printing to make models in both plastic and plaster
of knees, feet, pelvises, shoulder blades—“just about anything bony,” says Michalski. Physicians use these models to
teach young doctors, plan surgeries, and communicate with
patients. In the department of surgical research, doctors
are using Bio3D printers, which print live cells, to make not
models but the organs themselves, starting with blood vessels. 3D-printed organs, doctors hope, could eventually be
used in organ transplants.
Invented in the 1980s, 3D printers build up objects layer
by layer. The printer draws out one layer of “ink” (which can
be plastic, metal, plaster powder, wood composite, even
chocolate); the platform moves downward, and the printer
adds another layer atop the first. Successive strata form a
three-dimensional object in the same way that a surgeon
may use multiple cross-sectional images to envision a 3D
form. The printer follows a digital template; and luckily for
doctors, software can turn radiological data from MRI and
CT scans into these very guides.
In 2013, the raw materials that Michalski had at his
disposal included not just troves of radiological scans but
also 3D printers in the Yale Center for Engineering Innovation and Design (CEID). The CEID has five 3D printers, three
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of which are available to any Yale student or faculty member.
These open-access printers, produced by the New York Citybased company MakerBot, extrude melted plastic through a
heated tip that moves around the platform, creating a design
in the same the way a baker writes with frosting on a cake.
In mid-2013, Michalski started printing anatomical
objects on the MakerBot printers; his first print was a blue
plastic model of the chambers of a child’s heart. It was not
long before Michalski began to collaborate with the CEID’s
assistant director, Joseph Zinter, Ph.D., M.H.S. ’11, to 3Dprint models that could help surgeons. In June 2013, for
example, they printed a model of the tumor-invaded tibia
of a patient scheduled for surgery at Yale. “We brought the
model to the orthopaedic surgeon and said, ‘This is the case
you have on Thursday,’ ” recalls Zinter. The model helped the
surgeon plan an operative approach that would avoid cutting
the patient’s patellar tendon, says Zinter.
Based on the success of Michalski’s work at the CEID,
the Department of Diagnostic Radiology acquired its own 3D
printers in 2014. Radiology uses powder printers, a different type of 3D printer from those at the CEID. The powder
printer lays down a bed of powdered plaster and the printer
tip dispenses glue, causing the powder to stick together
where the tip writes. By the end of the print job, the object
is essentially buried in plaster dust, which supports the
structure as it is being printed; the unused powder is then
vacuumed away. (Since mid-2015, Michalski has worked full
time for a medical device company, the Butterfly Network,
of which he is president. As a research affiliate in the hospital’s diagnostic radiology department, though, he maintains
his ties to Yale and still does the occasional 3D print.)
Elliott Brown, M.D., HS ’12, FW ’13, who has led radiology’s 3D-printing program since Michalski left Yale,
explained how 3D printing helps physicians with their cases.
Some things are easy to understand from looking at a radiological image, says Brown, but in tricky cases, “a 3D model
is very helpful, because you get depth perception and you
get proprioception, meaning you can understand the shape
of an object by its feel.” Since it’s possible to drill into plaster,
the models also allow orthopaedic surgeons, who may need
to screw a patient’s bones back together, to test various
surgical approaches.
Beyond models, researchers want to print living organs
for patients awaiting organ transplants. In the ideal case,
these could be printed from cultured cells taken from the

recipient, eliminating both the wait for a donor organ and
the risk of immune system rejection.
This past summer, Yale’s department of surgical
research joined the effort to 3D-print organs when they
acquired a Bio3D printer through a partnership with the bioprinting company Organovo. John Geibel, D.Sc., M.D., M.S.,
vice chair of surgery, director of surgical research, professor of surgery and of cellular and molecular physiology,
and his colleagues began by printing blood vessels using
mixtures of rat smooth muscle, fibroblasts, and endothelial
cells. In a laboratory hood, the bioprinter lays down the “bio
ink,” strips of cells resembling ground meat, supported by

strips of a water-based gel. The result: a cylinder of cells
around a gel interior, which later can be removed to become
the lumen of the blood vessel. The next benchmark, says
Geibel, is to implant 3D-printed vessels into rats.
Eventually, Geibel would like to print a liver. During his
career, Geibel hopes to create a 3D-printed “assist liver”
that could be transplanted into patients and help them survive while they await a donor’s liver. “If we get that far,” says
Geibel, “it’s not impossible to think that we could eventually
create a complete replacement organ.”
—Ashley P. Taylor

ROBERT LISAK

A year ago Mark Michalski
was finishing up his
residency. Now he’s heading
a startup with millions of
dollars in financing and
dozens of employees.
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The tools
of medicine

From the first stone blades of the Neolithic
age to electronic health records, medical
advances have altered the relationship
between doctors and patients. And sometimes the technology has overwhelmed
the human touch.
By Jenny Blair, M.D. ’04
Pamela Moore Photo

The tools of medicine

There’s more than one way to secure an airway.
Emergency medicine residents and paramedics learn
early about the tools at our disposal to ensure that air
gets into a patient’s lungs. In my residency, we called
these tools airway toys, especially when we tried them
out at conferences. The right toy could save a life, and
there were always newfangled ones coming along.
So it goes throughout medicine today, with its explosion of new medical devices and the increasingly ubiquitous computer. Biologically, our bodies are largely
structured as they were in the Neolithic age, when practitioners used stone blades to carve holes in the skulls
of patients—who often survived the procedure. But our
instruments are now infinitely more complex, our era
the most tech-saturated in history. Many of us owe our
lives to the tools of medicine—including those that have
brought unforeseen consequences.
Diagnostic devices, for example, have quietly and
profoundly changed the doctor-patient relationship.
Such devices haven’t been around long, and the first
ones were comparatively simple. René Laennec’s 1816

In the mid-19th century,
Hermann von Helmholtz
invented the ophthalmoscope,
which allowed physicians to
observe the retina.
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stethoscope was a wooden tube; it impressed many,
not least those who were shy about laying an ear on
the chests of buxom women, but some physicians continued to rely on the old technique and on feeling the
patient’s pulse. In 1868, Carl Wunderlich published a
landmark work on monitoring body temperature—a
proposal that did not go over well with some of his
German colleagues steeped in a philosophical rather
than observational approach to medicine. Hermann
von Helmholtz used his ophthalmoscope to observe
the retina in 1850, wowing colleagues the following
year at the Great Exposition in London; in 1868,
John Aylwin Bevan wrote to The Lancet that he had
“discovered” a candle-powered esophagoscope, with
which “morbid growths, &c., can be clearly seen.”
In the meantime, laboratory medicine was beginning
to flower, thanks in part to the mid-19th-century
adoption of the medical microscope and advancements in histology over the latter half of that century.
Scipione Riva-Rocci gave the world the sphygmomanometer for measuring blood pressure in 1896, and

Willem Einthoven introduced the electrocardiograph—
it weighed 600 pounds and required five assistants
to operate it—in 1902. Wilhelm Roentgen’s X-rays
debuted in 1895, and dominated medical imaging until
the 1950s, 60s, and 70s saw the first ultrasounds,
CT scans, and MRIs.
is diagnosis a zero-sum game?

Today, among practitioners trained in modern imaging
and lab tests, practicing without them can seem almost
unthinkable. In 2005, doctors in the United States
ordered an estimated 1 billion needle punctures of
veins for blood sampling, and by 2007 they were ordering 80 million CTs a year.
Such wizardry can make diagnosis seem like a zerosum game. Why cultivate the difficult orally transmitted art of physical diagnosis when it’s so much quicker
and more accurate to order a study? In the process,
costs go up, along with such unintended consequences
as radiation-induced cancers from too many CT scans.
Or the patient can find himself parceled, body part
by body part, system by system, amongst specialists.
Or “incidentalomas” pop up, unexpected findings that
may not truly warrant treatment, but that can cause
anxiety and even harm from further testing. There is
also a loss of resiliency, something any tech-saturated
physician discovers if she tries practicing in a developing country and realizes she’s forgotten the difference
between S3 and S4 heart sounds. Back at home, we may
be just a power outage or hurricane away from discovering how much our effectiveness depends on these
technologies.
In fact, older physicians like Irwin Braverman,
M.D. ’55, HS ’56, professor emeritus of dermatology,
are concerned by what they see as a loss of physical diagnosis acumen among today’s house staff and
attendings—a phenomenon historians of technology
call deskilling. When Braverman trained, the most
admired senior physicians were highly observant and
sharply deductive. With X-rays their main confirmation tool, they had to be. “Physicians were using all
their senses plus whatever images they had to pull
things together. They were actually pretty good at it,”
Braverman says. Today, by contrast, he says, “the doctors’ cognitive skills keep declining because they rely

so much on technology.” (Ironically, at least one group
of technologies—simulators—can be used to train students in old-fashioned physical diagnosis skills.)
t h e s k i l l s h u m a n s b r i n g t o t h e ta s k

At worst, too much specialty testing can lead to a
potentially fatal valuing of abstraction over examination, a sort of cognitive abandonment of the patient.
Thomas P. Duffy, M.D., professor emeritus of medicine,
recalls a patient with fever, back pain, and neurological
findings whose physical exam suggested an epidural
abscess—an emergency that requires immediate treatment. Yet that treatment was delayed by the providers’ wish to schedule an MRI to confirm the diagnosis.
Somehow, the diagnosis seemed not to exist until a
machine said it did.
Yet these tests can uncover crucial information
that no physical exam ever could. The question, says
historian Joanna Radin, Ph.D., is how to combine
knowledge from scan results and the expertise of an
experienced physician, rather than reflexively valuing
one kind of knowledge over the other.
“There are many, many examples of the ways in
which technology has been introduced in a way that
doesn’t honor the skill and the richness of knowledge
that humans bring to a task,” says Radin, assistant
professor in the history of medicine, of anthropology, and of history. “Which isn’t to say that we should
reject technology—but it’s worth considering what
ways we want to deploy technology.”
w h e n o l d p r a c t i c e s f a l l b y t h e way s i d e

In the 1980s, amid bitter controversy, laparoscopy
transformed surgery. Inspired by gynecologists who
were employing the technique for tubal ligations in
the late 1970s, some pioneering surgeons tried it a
few years later for gallbladder removal and were vilified by their colleagues. What was then the standard
open surgical technique for gallbladder removal had
remained essentially unchanged since the 1940s.
Ultimately, though, laparoscopic cholecystectomy
became the gold standard for uncomplicated gallbladder disease, driven by patient demand and studies
finding advantages like less postoperative pain and
shorter hospital stays.
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Those attending surgeons who did make the switch
had to learn laparoscopy on the job; one study in
Germany found that this catching up meant temporarily depriving trainees of available cases.
There’s another problem, one that runs parallel
to what physicians like Braverman are noting: these
days, so many routine cholecystectomies are done via
laparoscopy that younger surgeons seldom use the
open technique any longer. If complications force them
to “convert” to the once-routine open procedure, the
surgeons’ inexperience could lead to patient harm. In
2012, a group of Harvard surgeons wrote that for that
very reason, open cholecystectomy is no longer the safe
alternative it once was. Last year, this situation led a
team of London historians to reenact 1980s-era open
cholecystectomies in a period operating suite with the
aid of retired surgeons and nurses, in the hope of preserving knowledge of the older technique.
technology is neither good nor bad — nor neutral

A koan-like axiom of the history of technology proposed by historian Melvin Kranzberg, Radin adds,
holds that technology is neither good nor bad—nor is
it neutral. Its value is all in how you roll it out.
There might be no more heated debate about that
idea today than the one that is taking place over
electronic health records (EHRs). As practitioners
and hospitals across the country scramble to switch
from paper records to meet federal benchmarks,
some commentators are pointing out unintended consequences. The promise of convenient record-sharing
and streamlined billing, not to mention access to
clinical data for studies, has been offset by design flaws
(like defaulting to the wrong measurement units);
high cost; and the alienating, time-consuming task
of data entry. It’s a less than ideal doctor-patient
encounter, after all, if the doctor is chiefly communicating with a computer monitor.
Yet EHRs, Radin says, can offer an opportunity
“to bring the technology more in alignment with
what makes a physician an excellent physician.” For
instance, a system may automatically rate physicians
for speed, forcing them to hurry through historytaking. What if, Radin asks, those same programs rated
the physicians for the number of adjectives they chose
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to describe the patient, guiding them to record a more
richly descriptive history?
Lisa Rosenbaum, M.D., made a similar point in an
October 22, 2015 New England Journal of Medicine
perspective piece.
“We measure many things that have no value to
patients, while much of what patients do value, including our attention, remains unmeasurable,” Rosenbaum
wrote. “The technology will support and improve
medical care only if it evolves in ways that help, rather
than hinder, us in synthesizing, analyzing, thinking
critically, and telling the stories of our patients.”
Better alignment of technology in this way requires
not only conversations between users and designers, but
also paying attention to what’s being lost, Radin says.
“Technology is always about changing human relationships,” she says. In the humble stethoscope, there is
precedent for such thoughtful design. In its modern
form, says Duffy, the stethoscope’s tubing isn’t the
optimum length for good acoustics: if it were, it would
be shorter. Rather, it represents a compromise between
good acoustics and the need to honor the patient’s personal space. The modern stethoscope can create an intimate yet respectful encounter, one that preserves the
solemnity and grandeur of professional mastery.
During auscultation, Duffy says, “No matter what
I hear, the patient is fascinated and always asks me,
‘What did you hear, doctor?’ … This is the beginning of
a wonderful trust, because of the hovering, listening,
[and] attention. It’s quiet, and it has a magic all its own.
We shouldn’t give that up.” /yale medicine
Jenny Blair, M.D. ’04, is a frequent contributor to Yale Medicine.

MICHAEL HELFENBEIN

A hunch leads to an anti-HIV compound
What if there were a natural compound that could prevent
HIV infection without damaging living cells? Batzelladine
B is such a compound. It was discovered in the late 1990s
in the red sponge from the Caribbean. But the process of
synthesis, or recreating it in the lab, proved complex and
lengthy. Seth Herzon, Ph.D., professor of chemistry and
pharmacology, whose lab focuses on natural product synthesis, recently discovered a new and efficient route for synthesizing batzelladine that makes it more readily available
for HIV-related research. With the shorter synthesis comes
the ability to modify the structures of batzelladine more
easily and make improved derivatives with better properties.
Batzelladine’s advantage is that it blocks the HIV protein
GP120 as it tries to bind with CD4 receptors on the membranes of immune system T cells. Once the protein binds,
the virus then injects its genomic information into the cell
where it replicates, bursting the T cell and spreading infection. Batzelladine binds to the T cell’s CD4 receptors and
prevents the HIV protein from fusing to the cell membrane.
Herzon’s team, which included postdoctoral associate
Brendan Parr, Ph.D., and graduate student Christos Economou,
hoped to find a faster way of synthesizing batzelladine. One
hurdle was that batzelladine contains nitrogen, an element
with conflicting attributes. It helps compounds interact with
biological systems, but it can also be unpredictable—requiring
extra steps to temper its reactivity. So the team used stable
ringed compounds called pyrroles as the molecular starting
point. “Making this connection allowed us to develop a very
short route that used about half of the steps other people have
needed to create similar structures,” Herzon explained.
Throughout the process Parr and Economou worked
through each reaction and then met with Herzon to brainstorm changes. “We began with what we thought would
happen and then ran the reaction. But as is common in
synthesis, what we thought would happen usually didn’t
occur,” said Herzon. “First, we had to understand what had
happened. Then, we tried to adjust how we were thinking
about the structure in order to think of new reactions that
might do what we wanted them to do.” For example, batzelladine consists of two fragments. While the first fragment
was created quickly, it took eight or nine approaches to the
second fragment before finding one that worked.
Just as no plan of battle survives the first shot, experiments require some artistic capacity and intuition. “It takes
a bit of faith, and willingness to go on your hunches,” he

said. For example, they had a hunch that they could control
nitrogen’s unpredictable nature until the last step in the
plan. This allowed them to consolidate 10 discrete chemical reactions into a single step. “We didn’t initially plan this,”
Herzon said. “But as the synthesis evolved we recognized
that [multiple reactions] were possible and we were able to
go for it.”
Once the synthetic plan was solidified, it was important
to ensure that each step and reaction yielded the maximum
amount of the chemical building block for the next step in
the process. Though time-consuming, this phase resulted in
a synthesis that requires only 15 steps and provides a good
quantity of batzelladine.
The project took about 18 months; batzelladine can now be
synthesized in about two weeks. This September, an interdisciplinary team, headed by Karen Anderson, Ph.D., professor of
pharmacology and of molecular biophysics and biochemistry,
began conducting further HIV research on batzelladine.
—Katherine L. Kraines

Seth Herzon discovered a compound found in red sponge that
could prevent HIV infection
without damaging living cells.
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capsule
Peter Meineck, Ph.D., clinical
professor of classics at New
York University, during his
lecture in August at summer
Psychiatry Resident Grand

		 Greek drama’s
lessons for veterans
		 A classics professor
helps veterans of war find their
voice through literature.
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The sea battle near Salamis was
a decisive victory of the GrecoPersian War in 480 BCE, when Greek
city-states united under Themistocles defeated King Xerxes of the
Persian Empire. The 19th-century
German painter Wilhelm von
Kaulbach depicted the battle that
took place between the Greek
mainland and the island of Salamis.

also served as a place of healing; they were often situated
next to hospitals and healing
centers. “It was their form
of mass cultural therapy,”
Meineck said.
Given the history of

opportunity to connect with
those who may have served

ancient Greece, these dramas

in Vietnam or Korea. Such

would have been written,

informal mentorship wasn’t

performed, and viewed by

part of his original vision, but

combat veterans—and now,

Meineck said it’s helped cre-

Meineck works to connect

ate a deeper sense of commu-

modern-day veterans with

nity. “I try to be really honest

the classics. “Even if they

about what we’re trying to

don’t know anything about

do, which is really just create

the Greeks, they get it,” he

a conversation,” he added.

said. “[The plays] speak to

Meineck, a native of Great

combat veterans, and I think

Britain, served in the Royal

they make it okay for combat

Marine Reserve himself as a

veterans to speak for them-

teenager during the Cold War,

selves, if they want. They

though he never saw com-

know that these are culturally

bat. But he has met count-

valued artifacts—so if these

less combat veterans who

culturally valued artifacts

understand Greek tragedies

seem to talk about their expe-

on a level different from that

riences, it actually creates an

granted by years of academic

environment where it’s okay

study. Some have found per-

for them to talk.”
For the last eight years,
Meineck has directed

RIGHT During the Civil War, reactions
to the battlefield were known as
“soldier’s heart.” In 1862, two photographers hired by Matthew Brady
produced the first images, taken
after the Battle of Antietam, to show
dead bodies on the battlefield. The
“Bloody Lane” was a sunken road
so crowded with dead bodies that it
slowed the Union advance.
BELOW The Imperial and Royal War
Press Bureau of the Austro-Hungarian Army, produced thousands of
photos from the front lines, including this one of a medical aid station.

sonal moments of catharsis
in reading the ancient works:
“One Vietnam veteran really

an organization called

broke down and said,

YouStories, which brings

‘I thought I had dealt with

veterans to the stage to

this. After 40 years, I thought

perform Greek tragedies

it had been dealt with,’ ”

and connect with civilian

recalled Meineck. “And it

audiences in a nuanced way.

was very shocking to him

The program isn’t offered

that it hadn’t been.” Their

by trained therapists, but

experiences allow veteran-

Meineck often hears that per-

actors to bring a new depth

forming together has helped

to the plays, offering an

veterans process their experi-

intensity and wisdom that

ences. The program also gives

even the best civilian actors

younger men and women

might otherwise be miss-

returning to the United States

ing. “You pick up the vibe of

from Iraq or Afghanistan an

As long as humans have waged war,
they have suffered from the psychological trauma of the battlefield. In
World War I this trauma was known
as “shell shock.” By the time of World
War II it was called combat stress
reaction or battle fatigue. Throughout history artists have depicted the
horrors of the battlefield in paintings,
plays, novels, songs, and film.

RIGHT The term "posttraumatic
stress disorder" came into use
in the late 1970s to describe the
trauma of veterans of the Vietnam
War. U.S. Army helicopters covered
a South Vietnamese infantry
advance with machine gun fire
in March 1965, as they moved to
attack a Viet Cong camp northwest of Saigon.

these men and women,” said
Meineck. “They have told me
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that they’re getting to speak
through this drama—and it’s
really quite indescribable, but
it’s remarkable.”
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			Alum sees place for
e-cigarettes in smoking cessation
I N T H E F I E L D O F T O B AC C O C O N T RO L , Michael B. Siegel, M.D. ’90, is a lone

wolf. The Boston University public health professor stands at odds with most
of his public health colleagues on one matter: e-cigarettes.
“Why so many public health
groups are trying to block them
is beyond me,” said Siegel.
“Cigarettes are highly toxic and
kill 400,000 people a year, while
e-cigarettes are not particularly
harmful and they’re helping
many people quit.”
During his medical internship
at Berkshire Medical Center in
Pittsfield, Mass., Siegel saw that
most people are admitted to the
hospital for preventable reasons:
smoking, alcohol, drugs, poor
diet, and lack of exercise. “We
can counsel every patient who
walks in the door about smoking,” he said, “but wouldn’t it be
more effective to have mass public
health campaigns that reduce
smoking? You’ll have a much larger
impact on the public’s health.”
That’s what led him to a
fellowship in the Centers for
Disease Control and Prevention’s
Office on Smoking and
Health after residency. “That
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experience convinced me that
I wanted to pursue an academic
career in public health.” But
smoking cessation had been
Siegel’s passion since he was an
undergraduate at Brown. There
he lobbied to make Rhode Island
the 13th state to ban smoking in
the workplace. During medical
school, he lobbied for tobacco
control laws in Connecticut.
Siegel believes that e-cigarettes
can make the big public health
impact he’s been waiting for.
Users inhale vaporized liquid
nicotine from the batteryoperated devices that sometimes resemble cigarettes.
Nothing burns. There is no
tobacco, no smoke, only vapor.
Hon Lik, a Chinese pharmacist and former heavy smoker,
invented e-cigarettes as a
smoking cessation device in
2003 after his father died of
lung cancer. Since the products came to the United States
in 2007, the FDA has regulated
them as tobacco products. A
misnomer, Siegel laments, that
undermines the good the products could do.

“More than 90 percent of
smokers who try to quit fail.
E-cigarettes work for them
because they simulate actual
smoking behavior—the hand
motion, the throat hit, the
holding of the cigarette, even
some of the social aspects. You
can [vape] with others in a
group,” Siegel said.
But the devices are not FDAapproved for smoking cessation,
so ads can’t say that vaping is
safer than smoking or that
e-cigarettes help smokers quit.
“You have a product that could
help the public, and you’re not
allowed to tell them what it does,”
Siegel said. “No one is arguing
that e-cigarettes shouldn’t be
regulated. The question is, How?”
To sell their wares, e-cigarette
makers resort to the same
advertising themes that tobacco
companies use—sex, freedom,
and independence. This, said
Siegel, tells smokers who might

M AT T H E W G U I L L O R Y P H O T O

Michael Siegel’s thinking
on e-cigarettes runs
counter to prevailing
views in the public health
community. He believes
that they are safer than
cigarettes and can help
people quit smoking.
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A grant helps a new
American pursue a
career in neuroscience.
Looking to her clerkship
years, a med student
learns about New Haven
Full stories and event
photo galleries, as well
as other online-only
content, can be found
on our home page at
yalemedicine.yale.edu.

otherwise try e-cigarettes that
these devices are just more of
the same.
Labeling e-cigarettes as
tobacco products, Siegel worries,
amounts to a missed opportunity E-cigarette opponents argue
that the products should be
for smokers. “The best thing is
banned or tightly regulated so
to quit smoking completely, but
that kids don’t take them up.
very few people are able to do
“I’m sure they will ban the sale
that.” For the rest, Siegel argues,
of these products to minors,
e-cigarettes are far less harmful
and to me, that’s a no-brainer.
than tobacco cigarettes. “You’re
It makes sense.”
no longer inhaling tens of thouBut that’s where Siegel’s and
sands of chemicals from tobacco
his peers’ common ground ends.
smoke, including more than
E-cigarette opponents argue that
60 known human carcinogens.”
vaping breeds nicotine addicSiegel doesn’t argue that the
tion and is a gateway to smoking.
products are completely harm“The majority of youth who use
less. Nicotine alone may pose
e-cigarettes are already smokers.
heart risks. It’s about harm
There are some who are nonreduction for those who would
otherwise smoke for life, he said. smokers who are just experimenting with these products.”
A 2015 review published in BMC
Siegel’s adversaries want to
Medicine cites emerging evikeep e-cigarettes from kids by
dence that smokers who switch
hiding them from view comto e-cigarettes show improvepletely. Siegel said just quit
ment in airway function and
telling kids e-cigarettes are
respiratory symptoms. A recent
sexy and tell them what they
study in the International
really are.
Journal of Environmental
“You don’t see kids using nicoResearch and Public Health
tine patches and nicotine gum.
showed similar outcomes in
That’s because they know that
smokers with asthma who
these are for smoking cessation.
switched to vaping.
And that’s not a cool thing.”
“There is a deeply entrenched
—Sonya Collins
ideology in tobacco control that,
one, anything that looks like
smoking could not possibly be
endorsed, and two, any addiction is terrible,” Siegel said.
Helping doctors help
This makes would-be vapers
themselves
think, “Why bother?” Siegel adds. Rows upon rows of manila
Perhaps the only issue
fi le folders sit like soldiers on
on which Siegel and his colthe credenza behind the desk
leagues see eye to eye is kids.
of DeWitt “Bud” C. Baldwin
Jr., M.D. ’49, where they have
a bird’s-eye view of Chicago’s
urban landscape and Lake
Michigan. Their contents fuel
the research that the

»
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93-year-old Baldwin conducts
as a scholar in residence at
the Accreditation Council for
Graduate Medical Education
(ACGME). Every day and often on
weekends too, he reads, thinks,
and writes in his 24th-floor
office, often about job burnout.
Not for his personal well-being,
but for the growing number of
trainees pushed to the brink by
their chosen profession.
Ironically, doctors—who are
drawn to helping others—suffer
high rates of depression, substance abuse, divorce, and suicide. Some 40 percent of medical
residents report feelings of
depression. As many as a dozen
take their own lives every year,
said Baldwin.
“Medicine today has become
too complex for the still-rigid way
we train physicians, leading to
an intense, nonsupportive learning environment,” said Baldwin,
who joined the American Medical
Association in the mid-1980s
to head the Office of Education
Research. There he launched
pioneering studies that revealed
disturbing findings: Medical
students and residents routinely
endured a great deal of mental
and physical abuse. “Years ago
I said, ‘It’s not just the hours [residents work] but what goes on in
those hours that matter.’ ”
Hired by the ACGME in
2002, Baldwin focuses on better understanding the resident experience. His research
helps to develop strategies and
guidelines that allow young
physicians to heal themselves

R AN DY LEE B ELI C E PH OTO

or at least let others help them.
To that end, Baldwin encourages trainees to speak up via a
variety of methods, including
anonymous surveys to measure
satisfaction and define the best
learning methods.
“Bud has provided a venue for
the voice of residents,” said Nick
Yaghmour, M.P.P., a research
analyst at the ACGME who
assists with Baldwin’s studies.
“He has brought the importance
of physician communication and
self-care into the discussion.”
A noted champion of humanism in medical education,
Baldwin has long advocated
reforming medical school curricula. For him, such soft
sciences as sociology and psychology are as important to
shaping future physicians as
the hard sciences of biology and
chemistry. He promoted the
once-radical notion that budding practitioners must learn
to appreciate that many factors
influence health, from socioeconomic status and cultural differences to gender and race.
A maverick throughout his more
than 60-year career, Baldwin
practiced what he preached at
four traditional and two new
medical schools he helped to
establish in Connecticut and
Nevada. One of the founders
of the Association for the
Behavioral Sciences and Medical
Education, he received the organization’s lifetime achievement
award in 2007.
This physician educator
didn’t stop at enhancing the

development of well-rounded
compassionate doctors. He also
introduced the concept of interprofessional teamwork: teaching
physicians and other health providers to care for patients with
a collaborative team approach,
for which he has received two
honorary doctorates. “I learned
to think health instead of disease,” said Baldwin, who applied
this model at the University of
Washington in Seattle in the
1950s. “When it comes to disease, doctors are the experts.
When it comes to health, doctors don’t know much. It’s the
nurses, social workers, nutritionists, dentists, and occupational therapists who help make
people healthy.” His tenure in
the Northwest also proved personally satisfying, as he met his
wife, Michele. A French native,
she was studying in the United
States on a Fulbright scholarship.
The couple has two daughters
and four grandchildren.
Baldwin credits much of his
passion for education to his parents, who believed in experiential,
small-group, and problem-based
learning. They were educational
missionaries in Burma (now
Myanmar), where Baldwin lived
until age 10. When they returned
to the United States in 1933, he
said, “They came back with the
belief that ‘We have as much to
learn as we have to teach’ and
were promptly fired by their mission board.”
While Baldwin’s ideas for
educational reform for physicians may have started decades

ago, they remain relevant
to graduate medical education. In early 2016, the ACGME
will bestow the first DeWitt C.
Baldwin Jr. award to an academic institution that demonstrates a humanistic culture and
fosters a respectful and supportive environment for medical education.
“Bud has taken the temperature of the soul of American residents in ways no one else has,”
said Timothy P. Brigham, M.Div.,
Ph.D., chief of staff and senior
vice president for education at
the ACGME. “He has touched
the lives of literally thousands
of physicians and, by extension,
thousands of patients who
have benefited from the impact
of his work.”
—Cheryl SooHoo

At 93, Bud Baldwin is still
hard at work, researching the experience of
residency and looking
for ways to help young
doctors in training deal
with depression, substance abuse, divorce,
and suicide. “It’s not just
the hours that residents work, but what
goes into those hours
that matters.”
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question and answer
How are you involved
with LGBTQ issues at
the School of Medicine?
Last year I was president of
the student group, OutPatient,
previously the Gay Straight

			 Why Nicole Sitkin adds
		 a plus sign to LGBTQI+
W H E N S E C O N D -Y E A R M E D I C A L S T U D E N T

Nicole Sitkin

speaks, her words flow quickly, her sentences packed

Medical Student Alliance. One
of our first orders of business was to change the name,
since it wasn’t inclusive of
the wonderful diversity of
identities and experiences of
LGBTQI+ folks. The “I” stands
for intersex, an identity term
sometimes used by people

with information, just as her professional life brims

who biologically don’t fall into

with accomplishments. In June 2013, the University

The plus sign is meant to

of California, Davis, awarded Sitkin the University
Medal, given to the top graduating senior who excels in
academics, community service, and promise of future
scholarship. In September 2014, Sitkin was appointed
to the Learning Environment Sub-Committee of the
Association of American Medical Colleges (AAMC)
Advisory Committee on Sexual Orientation, Gender
Identity, and Sex Development.

the male-female sex binary.
include whatever identities
or experiences people may
have. Additionally, last year I
approached Dean Schwartz
[Michael L. Schwartz, Ph.D.,
associate professor of neuroscience and associate dean
for curriculum] with a presentation on LGBTQI health
disparities, physicians’ power
to perpetuate or mitigate
those disparities, and the
first LGBTQI physician train-

She has co-authored nine peerreviewed research articles and
recently won a $5,000 medical
student leadership award from
Women In Medicine (WIM), a
national organization that provides medical education and
networking opportunities for
lesbian, gay, bisexual, transgender, and queer (LGBTQ)
female physicians. In November
2015, she earned a Best Poster
Presentation award in Public
Health at the American Medical

Association interim meeting.
Sitkin was subsequently elected
to the board of WIM. “Nix has
brought energy and clarity to
LGBTQ issues, especially as
they affect the education, practice, and professional experience of medical students and
physicians. She has a voice
in national discussions,” said
Forrester A. Lee, M.D. ’79,
HS ’83, associate dean for multicultural affairs and professor
of medicine (cardiology). Sitkin
recently sat down with Yale
Medicine to talk about her work
on LGBTQ issues.

{ To nominate a subject for Q&A, contact

Yale Medicine, 1 Church Street, Suite 300, New Haven, CT 06510 or email ymm@yale.edu
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ing guidelines, issued by the
AAMC in 2014. That conversation blossomed into an ongoing
collaborative effort between
faculty, staff, and students to
incorporate new and enhance
existing LGBTQI health content in the curriculum.

What might a sample of
medical education on
LGBTQ health look like?
Our idea is to provide training like a spiral staircase.

Q&A WITH

Nicole
Sitkin

CONDUCTED BY

affect whether students feel

Kathleen Raven

comfortable and safe being
out. I know students who
are uncertain about whether
they can be out in their proYou start at the bottom with

fessional lives. For people

dean for student affairs] and

the facts. For example, what

who are figuring it out or are

Dean Lee is what we can do

do the terms LGBTQ, inter-

coming out, it’s so impor-

to institutionalize LGBTQI

sex, and cisgender mean?

tant to be able to connect.

programming in terms of

How does sex differ from

I’m out, I have a partner I’m

formal curriculum, support

gender, which differs from

crazy and open about, and

services, and educational

sexual orientation? As stu-

I still benefit so much from

opportunities for

dents progress, they acquire

interacting with supportive

the whole health campus.

communication tools, such

allies and LGBTQ role models

We are actively seeking

as by practicing inclusive

and mentors at the School

to bring together people,

interviewing with standard-

of Medicine. At Yale, we are

LGBTQI and allies, and

ized patients. During clerk-

bringing together faculty,

to identify resources to

ships, students then have the

staff, and other resources to

support this work. We

opportunity to reflect on real

provide more visible, acces-

welcome the involvement

patient care experiences and

sible support for students.

to hone and implement their
knowledge and communication skills.

of any Yale community
members interested in

What is your partner,
Mariko Zelin, doing now?

LGBTQI health.

Mariko is a gifted research

In your experience, do
peers feel comfortable
being “out” on medical
school campuses? There

scientist. She’s currently
doing research at a start-up
company while completing
a master’s of science in bio-

has been limited institu-

technology at Northwestern

tional support for sexual and

University. She’ll be graduat-

gender minority individuals

ing in December and moving

at medical schools histori-

to New Haven. She’s excited

cally. Fortunately, the cul-

to explore the opportunities

ture of medical education

in the biopharmaceutical

is shifting in parallel with

industry out here.

society generally, to greater
respect and recognition of
the lives and identities of
LGBTQI folks. That being

What can people do
to support the LGBTQI+
community? One of the

said, everyone’s experience

ideas I’ve talked about with

is different. Some folks may

Dean Angoff [Nancy R.

never want to be “out” in a

Angoff, M.P.H. ’81, M.D. ’90,

professional context, while

HS ’93, associate profes-

it may be very important to

sor of medicine (general

others to have their identity

medicine) and associate

recognized. Institutional
TERRY DAGRADI PHOTO

culture and visible support systems also deeply
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book review
His daughter was there, too:
“People talk about Army brats,
and there was such a thing
at NIH. I grew up around all
the oncologists,” said DeVitacarried beepers.”
Her mantra was to make

By Cathy Shufro

argues DeVita, “The war on
cancer is being won, though

the book “relentlessly use-

the general tenor in the

ful.” It warns that when a

press is that it’s not.” That

doctor is willing to reduce a

may be because reporters

chemotherapy dose to mini-

focus on short-term setbacks,

mize horrible side effects, or

not the big picture, says

schedules treatments based

DeVita-Raeburn.

on convenience rather than

		Winning
the war on cancer

patient survival. Nonetheless,

Overall cancer mortality

the life cycles of cancer

has dropped by 25 percent

cells, that doctor might be

since the 1990s. Due to three

knocking out a patient’s best

paradigm shifts, beginning

chance of survival. It advises

in the 1960s with the rec-

readers that no name-brand

ognition that combination

cancer center, including

chemotherapies worked better

Yale’s, can offer optimal

than single drugs, DeVita and

treatment for every type of

colleagues designed a four-

cancer; different institutions

drug treatment that for the

do better with different can-

first time cured patients with

cers. It provides recommen-

advanced Hodgkin’s disease,

the Front Lines of Medicine,

dations, with the caveat that

for which he won a presti-

HS ’66, had “zero interest in

a Pioneering Oncologist

they’ll soon be outdated.

cancer” when he began a fel-

Reveals Why the War on

Vincent T. DeVita Jr., M.D.,

The book begins by

gious Lasker Award in 1972.
At a time when most tumors

lowship at the National Cancer

Cancer Is Winnable—and

describing how DeVita

Institute (NCI) in 1963. But

How We Can Get There.

thought through which

and radiation, the treatment

prostate cancer treatments

proved that chemotherapy

DeVita, because, “The people

to suggest to a family friend.

could vanquish cells that

who have put over $100 billion

It closes with the story of

escape tumors to enter the

into the war on cancer have

DeVita himself, who suffered

bloodstream or organs. The

he decided that even cancer
research sounded better than
“getting shot at in Vietnam.”
The Death of Cancer fol-

They wrote the book, says

lows DeVita’s transformation

the right to know what was

from a reluctant researcher to

done with it.”

a leader in a struggle that he

It’s a story that DeVita,

“the double curse of being
a doctor who gets a disease

were treated with surgeries

second shift was the advent
of targeted therapies, which

from his own field.” The book

can turn cancer into a chronic

says we’re winning. DeVita

now 80, has witnessed at

explains how he charted his

rather than a fatal disease.

communicates that same

NCI and on Capitol Hill, at

own cancer treatment. (He

The third shift derives from

optimism in the hefty subtitle

Memorial Sloan Kettering

says he’s doing fine.)

new approaches that use a

of the book that he wrote with

Cancer Center in New York,

his daughter, science writer

and at Yale Cancer Center,

illustrates how greed, turf

Elizabeth DeVita-Raeburn,

which he directed for a decade.

wars, and myopia have often

M.P.H.: After Fifty Years on

At NCI, part of the National

obscured the central goal of

The Death of Cancer

to quell cancer.
“The best is yet to come,”
said DeVita. “I think you’re

Institutes of Health (NIH), he

going to see some really star-

climbed the ranks to serve

tling stuff in the next five or

as director from 1980 to 1988.

10 years.”

{ Send notices of new books to

Yale Medicine, 1 Church Street, Suite 300, New Haven, CT 06510 or email ymm@yale.edu
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patient’s own immune system

T E R R Y D A G R A D I P H O T O ; O P P O S I T E PA G E , J O H N C U R T I S P H O T O

Raeburn. “I thought all men

end note

Not by the numbers
L U N C H T I M E PA I N T I N G B E C O M E S A B R E A K F RO M T H E O F F I C E .

Ni La and Roshni

Srivastava, researchers in cardiovascular medicine, were among about 30 Yale workers,
ranging from postdocs at the School of Medicine to IT techs to administrative assistants,
who spent a lunch break painting in August. Being Well at Yale sponsors the painting
class as a way to ease the stress of the workplace.
“We’re looking for a creative way to encourage employees to step away from the office for
a little bit, recharge, and reset,” said Lisa Kimmel, manager of Being Well at Yale. Art Plus
Studio on Chapel Street hosts the once-a-month painting sessions. Rachel Rasfeld,
an instructor at the studio, guided the painters through the process. “It’s like art therapy.
We do a painting together, but the point is to relax,” Rasfeld said.
—John Curtis

view a video on the lunchtime art class,
{ To
visit yalemedicine.yale.edu/art

